Log in with your email address username.


[Correspondence] Effect on death of scaffold thrombosis versus stent thrombosis

The meta-analyses by Salvatore Cassese and colleagues1 and by Gregg Stone and colleagues2 recently published in The Lancet compared a drug-eluting stent Xience (Abbott; Chicago, USA) with a bioresorbable vascular scaffold Absorb (Abbott; Chicago, USA) in patients with coronary artery disease, with the aim of filling the gap left by the last biggest randomised trial, ABSORB-III.3 Indeed, the number of patients investigated in ABSORB-III was too low to give an accurate and clear opinion regarding Absorb.